Protein PHGDH may predict immunotherapy success in colorectal cancer
NCT ID NCT07508046
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study from West China Hospital examined tumor tissue from 100 colorectal cancer patients who had already received immunotherapy. Researchers measured levels of a protein called PHGDH to see if it was linked to how well the patients responded to treatment and how long they lived. The goal was to find a simple marker that could help guide future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If PHGDH proves to be a reliable marker, doctors could one day use it to decide which colorectal cancer patients are most likely to benefit from immunotherapy.
What could go wrong
This is an observational study that only looks back at existing data. It does not test a new treatment, so any link between PHGDH and outcomes is still unproven and needs much larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital
Chengdu, Sichuan, 610041, China